Related Experiment Video
Updated: Jul 1, 2026
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
The endocannabinoid system in Parkinson's disease
Massimiliano Di Filippo1, Barbara Picconi, Alessandro Tozzi
1Clinica Neurologica, Ospedale S. Maria della Misericordia, Universita' di Perugia, 06156 Perugia, Italy.
Current Pharmaceutical Design
|September 11, 2008
Summary
Parkinson's disease involves the degeneration of dopamine neurons. Targeting the endocannabinoid system offers potential therapeutic strategies for motor function and neuroprotection in Parkinson's disease.
Area of Science:
- Neuroscience
- Neurodegenerative Diseases
- Pharmacology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta.
- The endocannabinoid (ECB) system is integral to basal ganglia function, interacting with key neurotransmitter systems including dopaminergic, glutamatergic, and GABAergic signaling.
Purpose of the Study:
- To explore the role of the endocannabinoid system in the pathophysiology of Parkinson's disease.
- To evaluate the potential of targeting the ECB system for therapeutic interventions in PD.
Main Methods:
- Review of existing literature on the endocannabinoid system and Parkinson's disease.
- Analysis of the interaction between ECB signaling and dopaminergic pathways in the basal ganglia.
Main Results:
- Endocannabinoids (ECBs) critically modulate synaptic transmission and plasticity, particularly long-term depression, at synapses within the basal ganglia.
- Significant alterations in ECB signaling are observed in experimental models and human patients with PD following dopamine depletion.
Conclusions:
- The endocannabinoid system plays a crucial role in regulating basal ganglia physiology and motor control.
- Targeting the ECB system presents a promising avenue for developing symptomatic and neuroprotective therapies for Parkinson's disease.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...